Adragos Pharma announces a leadership transition as the company enters its next phase of development.
On the sixth anniversary of the company’s founding, Dr. Andreas Raabe, Founder of Adragos, will step down from his role as CEO. Under his leadership, Adragos has developed into a multinational CDMO operating across six sites in five countries, establishing itself as a reliable partner in the pharmaceutical outsourcing market.
Dr. Raabe will remain a shareholder of Adragos and will continue to support the company in an advisory capacity.
Kostas Rengis will assume the role of CEO of the Adragos Group effective May 1st. He brings deep experience leading international multi-site operations and complex pharmaceutical networks across manufacturing, commercial and R&D, with a strong track record in integrating sites and improving performance in CDMO and industrial environments. Under his leadership, Adragos will focus on strengthening its platform, integrating capabilities across the network, and translating them into reliable and consistent delivery for its customers.
The transition has been structured to ensure continuity for customers, partners, and employees, with a defined handover period supporting the ongoing reliability of Adragos as a partner to all stakeholders.
About Adragos Pharma
Adragos Pharma is a fast-growing global CDMO headquartered in Munich, Germany. Leveraging a network of seven manufacturing sites across Europe and Japan, we provide end-to-end pharmaceutical services from development through commercial manufacturing to support our clients. With advanced technical exper-tise and a customer-centric approach, we deliver high-quality, reliable solutions that meet the evolving needs of the pharmaceutical industry.
